Welcome to AiCuris: The Powerhouse for Anti-infectives    


“Committed to making the difference”

AiCuris is a pharmaceutical company focused on the discovery, research and development of novel, resistance-breaking antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases.

Founded in 2006 as a spin-out from Bayer's virology and bacteriology research department, AiCuris is now an established “powerhouse for anti-infectives” and is one of the few biotech companies world-wide to have successfully brought a drug to market, and therefore to patients (Prevymis® 2017/18).

Today AiCuris has an innovative pipeline of anti-infective agents and a team of internationally recognized scientists in Research and Development. By focusing on therapeutic areas with high medical need, the company is positioned for growth and success.

Corona diagnostic support for NRW

Together with state-run veterinary institutes in NRW AiCuris is involved in carrying out approximately 20,000 tests against SARS-CoV-2

• Following the increased incidence of coronavirus infections among employees of a slaughterhouse in Coesfeld, all of the approx. 20,000 employees and contract workers of slaughterhouses in NRW are currently being tested 
• AiCuris has been involved at many levels since the outbreak of the pandemic and has established and made available SARS CoV-2 testing capacities at short notice to contribute to the fight against the corona pandemic


Read more ...

Early Access Program for Pritelivir

AiCuris collaborates with myTommorrows to initiate an Early Access Program for Pritelivir
  • The Early Access Program may provide access to Pritelivir for use in immunocompromised patients that have acyclovir-resistant mucocutaneous herpes simplex virus infections
  • An Early Access Program offers a method to provide patients with an unmet medical need with possible access to medication currently not licensed in their home country

You're a patient or a doctor interested in the program? Please find more information here

Read more ...

AiCuris Provides Corporate Update

AiCuris Anti-infective Cures GmbH today provided a strategic update, outlining its recent achievements and plans for future growth.
  • Over 15,000 patients worldwide already treated with Letermovir to prevent Cytomegalovirus (CMV) infection and disease in allogeneic stem cell transplantation
  • Pritelivir in Phase 2 testing for treatment of Acyclovir resistant HSV infections in immune-comprised patients; AiCuris is preparing a pivotal Phase 3 trial
  • AIC649, a potential cure for chronic hepatitis B, to be partnered
  • Company fully dedicated to develop novel antibiotics to combat antimicrobial resistance
  • Significant ongoing revenue stream provides funding to carry out ambitious plans

Read more ...